Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06271681
PHASE4
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Sponsor: VA Sierra Nevada Health Care System
View on ClinicalTrials.gov
Summary
The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2026-01-01
Completion Date
2027-06-01
Last Updated
2025-08-14
Healthy Volunteers
No
Conditions
Interventions
DRUG
21-valent pneumococcal conjugate vaccine
FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment